Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 4/2020

01-12-2020 | Glucocorticoid

Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders

Authors: Yanduan Lin, Ziwei Zhang, Siyu Wang, Jinyan Cai, Jiao Guo

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2020

Login to get access

Abstract

With the change of life style, glucolipid metabolic disorders (GLMD) has become one of the major chronic disorders causing public health and clinical problems worldwide. Previous studies on GLMD pay more attention to peripheral tissues. In fact, the central nervous system (CNS) plays an important role in controlling the overall metabolic balance. With the development of technology and the in-depth understanding of the CNS, the relationship between neuro-endocrine-immunoregulatory (NEI) network and metabolism had been gradually illustrated. As the hub of NEI network, hypothalamus-pituitary-adrenal (HPA) axis is important for maintaining the balance of internal environment in the body. The relationship between HPA axis and GLMD needs to be further studied. This review focuses on the role of HPA axis in GLMD and reviews the research progress on drugs for GLMD, with the hope to provide the direction for exploring new drugs to treat GLMD by taking the HPA axis as the target and improve the level of prevention and control of GLMD.
Literature
1.
Ye DW, Rong XL, Xu AM, Jiao G. Liver-adipose tissue crosstalk: a key player in the pathogenesis of glucolipid metabolic disease. Chinese Journal of Integrative Medicine. 2017;23:410–4.PubMed
2.
G. Jiao. Research Progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine, Chinese Journal of Integrative Medicine.
3.
Kagaku A, Qian Z, Masami N, et al. Association between mastication, the Hippocampus, and the HPA Axis: a comprehensive review. Int J Mol Sci. 2017;18:1687.
4.
Luo QH, Chen SS, Deng J, et al. Endocannabinoid hydrolase and cannabinoid receptor 1 are involved in the regulation of hypothalamus-pituitary-adrenal axis in type 2 diabetes. Metab Brain Dis. 2018;33:1483–92.PubMed
5.
Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374–81.PubMed
6.
Aguilera G, Liu Y. The molecular physiology of CRH neurons. Front Neuroendocrinol. 2012;33:67–84.PubMed
7.
Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry. 2002;7:254–75.PubMed
8.
Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disorders. J Allergy Clin Immunol. 2013;132:1033–44.PubMedPubMedCentral
9.
Finsterwald C, Alberini CM. Stress and glucocorticoid receptor-dependent mechanisms in long-term memory: from adaptive responses to psychopathologies. Neurobiology of Learning & Memory. 2014;112:17–29.
10.
Shen YC, Roh HC, Kumari MJ, et al. Adipocyte glucocorticoid receptor is important in lipolysis and insulin resistance due to exogenous steroids, but not insulin resistance caused by high fat feeding.[J]. Mol Metab. 2017;6:1150–60.PubMedPubMedCentral
11.
Vispute SG, Bu PL, Le Y, et al. Activation of GR but not PXR by dexamethasone attenuated acetaminophen hepatotoxicities via Fgf21 induction.[J]. Toxicology. 2017;378:95–106.PubMed
12.
Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disorders: an epidemiological approach. Clin Endocrinol. 2010;40:479–84.
13.
W.J. Young. Clinical practice, The incidentally discovered adrenal mass, New England Journal of Medicine,2007, 356: 601.
14.
Sapolsky RM. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21:55–89.PubMed
15.
M.F. Dallman, S. Bhatnagar. Chronic Stress and Energy Balance: Role of the hypothalamic pituitary adrenal axis, 2011.
16.
Chrousos GP. The role of stress and the hypothalamic–pituitary–adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. International Journal of Obesity. 2000;24(Supplement 2):S50–5.PubMed
17.
Ivana MD. Hyperactivity of the hypothalamic-pituitary-adrenal axis in patients with type 2 diabetes and relations with insulin resistance and chronic complications. Wien Klin Wochenschr. 2012;124:403–11.
18.
Beauquis J, Homo-Delarche FO, Giroix M-H, et al. Hippocampal neurovascular and hypothalamic–pituitary–adrenal axis alterations in spontaneously type 2 diabetic GK rats. Experimental Neurology. 2010;222:125–34.PubMed
19.
Tagawa N, Kubota S, Kato I, Kobayashi Y. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes. J Endocrinol. 2013;218:311–20.PubMed
20.
Park SB, Jung WH, Kang NS, Park JS, Bae GH, Kim HY, et al. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice. Eur J Pharmacol. 2013;721:70–9.PubMed
21.
Ezhumalai M, Radhiga T, Pugalendi KV. Antihyperglycemic effect of carvacrol in combination with rosiglitazone in high-fat diet-induced type 2 diabetic C57BL/6J mice. Mol Cell Biochem. 2014;385:23–31.PubMed
22.
Nemanich ST, Rani S, Shoghi K. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats. Obesity. 2013;21:2522–9.PubMed
23.
Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;13:2166–70.
24.
Mai K, Reinecke F, Andres J et al. Effects of hyperlipidaemia on glucocorticoid metabolism: results of a randomized controlled trial in healthy young women.[J]. Clin. Endocrinol. (Oxf), 2011, 74: 551–7.
25.
Xiong F, Zhang L. Role of the hypothalamic-pituitary-adrenal axis in developmental programming of health and disorders. Frontiers in neuroendocrinology. 2013;34:27–46.PubMed
26.
Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11B-Hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001;276:41293–300.PubMed
27.
Wang JZ, Cao HX, Chen JN, et al. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disorders. World Journal of Clinical Cases. 2018;6:11–9.
28.
Kershaw EE, Flier JS, et al. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;18:2548–56.
29.
Angulo P. Nonalcoholic fatty liver disorders — NEJM. Ann Epidemiol. 2013;58:1435–7.
30.
Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic Steatohepatitis. Diabetes Care. 2004;27:2057–66.PubMed
31.
A. Cordeiro Adryana, R. Costa Raquel, N. Andrade et al. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disorders in obesity?[J]. Clin Res Hepatol Gastroenterol, 2020.
32.
Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled type 2 diabetic patients [J]. Diabet Med. 2005;22(9):1146–50.PubMed
33.
W.B. Wang, F. She, L.F. Xie. Evaluation of basal serum adrenocorticotropic hormone and cortisol levels and their relationship with nonalcoholic fatty liver disorders in male patients with idiopathic Hypogonadotropic Hypogonadism [J]. National Medical Journal of China, 2016, 129.
34.
Carril E, Valdecantos MP, Lanzón B, et al. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet.[J]. J Pharm Biomed Anal. 2020;178:112958.PubMed
35.
Jung FU, Bae YJ, Kratzsch J, et al. Internalized weight bias and cortisol reactivity to social stress.[J]. Cogn Affect Behav Neurosci. 2020;20:49–58.PubMed
36.
Ito E, Shima R, Yoshioka T. A novel role of oxytocin: Oxytocin-induced well-being in humans.[J]. Biophys Physicobiol. 2019;16:132–9.PubMedPubMedCentral
37.
Glantschnig C, Mattijssen F, Vogl ES, et al. The glucocorticoid receptor in brown adipocytes is dispensable for control of energy homeostasis.[J]. EMBO Rep. 2019;20:e48552.PubMed
38.
R.A. Miranda, R. Torrezan, Júlio Cezar de Oliveira, et al. HPA-axis and vagus nervous function are involved in impaired insulin secretion of MSG-obese rats [J]. Journal of Endocrinology, 2016, 230(1): JOE-15-0467.
39.
Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary-adrenal Axis in humans. Hormone & Metabolic Research. 2000;32:521–5.
40.
Hepsen S, Sencar E, Sakiz D, Akhanli P, Ucan B, Unsal I, et al. Serum cortisol level after low dose dexamethasone suppression test may be predictive for diabetes mellitus and hypertension presence in obese patients: a retrospective study.[J]. Diabetes Res Clin Pract. 2020;161:108081.PubMed
41.
Puustinen T, Tervonen Joona J, Avellan C, et al. Psychiatric disorders are a common prognostic marker for worse outcome in patients with idiopathic intracranial hypertension.[J]. Clin Neurol Neurosurg. 2019;186:105527.PubMed
42.
Elian AH, Maribel HR, Rubén RR, et al. Effect of Ocimum basilicum, Ocimum selloi, and Rosmarinic Acid on Cerebral Vascular Damage in a Chronic Hypertension Model.[J]. Biol. Pharm. Bull. 2019;42:201–11.
43.
Vieira Jonas O, Duarte Josiane O, Willian C-F, et al. Influence of pre-existing hypertension on neuroendocrine and cardiovascular changes evoked by chronic stress in female rats.[J]. Psychoneuroendocrinology. 2018;97:111–9.PubMed
44.
Luo Y, Zhang DG, Chen YL, et al. Dexamethasone protects against arsanilic acid-induced rat vestibular dysfunction through the BDNF and JNK 1/2 signaling pathways.[J]. Mol Med Rep. 2019;19:1781–90.PubMed
45.
Niu N, Xu SW, Xu YN, et al. Targeting Mechanosensitive Transcription Factors in Atherosclerosis.[J]. Trends Pharmacol. Sci. 2019;40:253–66.PubMedPubMedCentral
46.
Kaplan JR, Manuck SB. Status, stress, and atherosclerosis: the role of environment and individual behavior. Ann N Y Acad Sci. 2010;896:145–61.
47.
Zieff G. Ancient roots - Modern applications: Mindfulness as a novel intervention for cardiovascular disorders.[J]. Med. Hypotheses. 2017;108:57–62.PubMed
48.
Salminen A, Kaarniranta K, Kauppinen A. Regulation of longevity by FGF21: interaction between energy metabolism and stress responses.[J]. Ageing Res. Rev. 2017;37:79–93.PubMed
49.
Chen JJ, Tao J, Zhang XL, et al. Inhibition of the ox-LDL-Induced Pyroptosis by FGF21 of Human Umbilical Vein Endothelial Cells Through the TET2-UQCRC1-ROS Pathway.[J]. DNA Cell Biol. 2020;10:1089.
50.
Evans JF, Ragolia L. Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis. Med Hypotheses. 2012;79:823–6.PubMedPubMedCentral
51.
Teich T, Dunford EC, Porras DP, et al. Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.[J]. Am. J. Physiol. Endocrinol. Metab. 2016;311:E56–68.PubMedPubMedCentral
52.
Priyadarshini E, Anuradha CV. Glucocorticoid Antagonism Reduces Insulin Resistance and Associated Lipid Abnormalities in High-Fructose-Fed Mice.[J]. Can J Diabetes. 2017;41:41–51.PubMed
53.
Zhu KC, Zhang YM, Zhang J, et al. Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion.[J]. Toxicol. Lett. 2020;320:19–27.PubMed
54.
Nagasawa K, Matsuura N, Takeshita Y, et al. Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486.[J]. Nutr Diabetes. 2016;6:e207.PubMedPubMedCentral
55.
Thomas W, Noah T, Kym PR, et al. Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.[J]. J. Med. Chem. 2004;47:4213–30.
56.
Zinker B, Mika A, Nguyen P, Wilcox D, Öhman L, von Geldern TW, et al. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance.[J]. Metab Clin Exp. 2007;56:380–7.PubMed
57.
Tomlinson JW, Stewart PM. Modulation of glucocorticoid action and the treatment of type-2 diabetes.[J]. Best Pract. Res. Clin. Endocrinol. Metab. 2007;21:607–19.PubMed
58.
Pereira CD, Azevedo I, Monteiro R. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus [J]. Diabetes Obes Metab. 2012;14:869–81.PubMed
59.
Kroon J, Koorneef LL, Jose K, et al. Selective Glucocorticoid Receptor Antagonist CORT125281 Activates Brown Adipose Tissue and Alters Lipid Distribution in Male Mice.[J]. Endocrinology. 2018;159:535–46.PubMed
60.
Nguyen ET, Berman S, Streicher J, et al. Effects of combined glucocorticoid/mineralocorticoid receptor modulation (CORT118335) on energy balance, adiposity, and lipid metabolism in male rats.[J]. Am. J. Physiol. Endocrinol. Metab. 2019;317:E337–49.PubMed
61.
Koorneef LL, José K, Kroon KJ, et al. Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver disorders in Male Mice.[J]. Endocrinology. 2018;159:3925–36.PubMed
62.
Stephens Jeffrey W, Brown Karen E, Thinzar M. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.[J]. Diabetes Obes Metab. 2020;22:32–45.PubMed
63.
Daisuke S, Eiichiro Y, Kenichi T. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.[J]. Curr. Hypertens. Rep. 2020;22:21.
64.
Satoshi M, Atsuhiro I. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.[J]. Hypertens. Res. 2020;43:744–53.
65.
Fuller Peter J, Yao Yi-Zhou, Yang Jun et al. Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective.[J] .J Hum Hypertens, 2020.
66.
Wan Ningning, Rahman Asadur, Nishiyama Akira, Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.[J] .J Hum Hypertens, 2020.
67.
Granberg Kenneth L, Zhong-Qing Y, Bo L, et al. Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.[J]. J. Med. Chem. 2019;62:1385–406.PubMed
68.
George B, Fred YY, Bertram P. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.[J]. Hypertension. 2020;76:144–9.
69.
Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo [g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.[J]. J Med Chem. 2010;53(16):5979–6002.PubMed
70.
Nariai T, Fujita K, Mori M, et al. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats.[J]. Journal of Cardiovascular Pharmacology. 2012;59(5):458.PubMed
71.
Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule [J]. J Biol Chem. 2010;285(39):29932–40.PubMedPubMedCentral
72.
Chen ZF, Zhang L, Yi JY, et al. Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARγ-agonist activity. J Cell Biochem. 2012;113:3547–58.PubMed
73.
Mahmoud MF, Hassan NA, Bassossy HM, et al. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation [J]. PLoS One. 2013;8:63784.
74.
Zhao HL, Sim JS, Shim SH, Ha YW, Kang SS, Kim YS. Antiobese and hypolipidemic effects of platycodin saponins in diet-induced obese rats: evidences for lipase inhibition and calorie intake restriction. Int J Obes. 2005;29:983–90.
75.
Wu SY, Wang GF, Liu ZQ, et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Chinese Journal of Pharmacology. 2009;30:202–8.
76.
Yoshinari O, Igarashi K. Anti-diabetic effect of trigonelline and nicotinic acid, on KK-A(y) mice. Curr Med Chem. 2010;17:2196–202.PubMed
77.
Accatino L, Pizarro M, Solis N, et al. Effects of diosgenin, a plant-derived steroid, on bile secretion and hepatocellular cholestasis induced by estrogens in the rat. Hepatology. 2010;28:129.
78.
J.D. Lu, L.J. Fu, G.Z. Qin, et al. The regulatory effect of Xiaoyao San on glucocorticoid receptors under the condition of chronic stress, Cellular and molecular biology (Noisy-le-Grand, France), 2018, 64 : 103–109.
79.
P. Meng, H.Z. Huang, Q. Yang, et al. Kangai Jieyu fang, a Chinese herbal formulation, Ameliorates Cancer-Related Depression Concurrent with Breast Cancer in Mice via Promoting Hippocampal Synaptic Plasticity, Evidence-based complementary and alternative medicine : eCAM, 2018: 3967642.
80.
Pao LH, Lu SW, Sun GG, Chiou SH, Ma KH. Three Chinese herbal medicines promote neuroproliferation in vitro, and reverse the effects of chronic mild stress on behavior, the HPA axis, and proliferation of hippocampal precursor cell in vivo. J Ethnopharmacol. 2012;144:261–9.PubMed
81.
Lee WY, Jang SW, Lee JS, Kim YH, Kim HG, Han JM, et al. Uwhangchungsimwon, a traditional herbal medicine, protects brain against oxidative injury via modulation of hypothalamus–pituitary–adrenal (HPA) response in a chronic restraint mice model. J Ethnopharmacol. 2014;151:461–9.PubMed
82.
Wang S, Wang C, Yu Z, et al. Agarwood essential oil ameliorates restrain stress-induced anxiety and depression by inhibiting HPA Axis hyperactivity. Int J Mol Sci. 2018;19.
83.
Li HY, Zhao YH, Zeng MJ, Fang F, Li M, Qin TT, et al. Saikosaponin D relieves unpredictable chronic mild stress induced depressive-like behavior in rats: involvement of HPA axis and hippocampal neurogenesis. Psychopharmacology. 2017;234:3385–94.PubMed
84.
Esmaeili MH, Bahari B, Salari AA. ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disorders. Brain Res Bull. 2018;137:265–76.PubMed
85.
Xia X, Yang JH, Sheng YF, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One. 2011;6:16556.
86.
Mi J, He WD, Lv JW, et al. Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats.[J]. Diabetes Metab Syndr Obes. 2019;(12):1717–25.
87.
Rami BK, Viviane S, Youakim S, et al. Mifepristone reduces hypothalamo-pituitary-adrenal axis activation and restores weight loss in rats subjected to dietary restriction and methylphenidate administration. Neurosci Res. 2018;135:46–53.
88.
Zhou J, Wang D, Luo XH, Jia X, Li MX, Laudon M, et al. Melatonin receptor agonist Piromelatine ameliorates impaired glucose metabolism in chronically stressed rats fed a high-fat diet. J Pharmacol Exp Ther. 2018;364:55–69.PubMed
89.
Zhou J, Zhang J, Luo XH, Li MX, Yue Y, Laudon M, et al. Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in rats. Eur J Pharmacol. 2017;812:225–33.PubMed
90.
Perry RJ, Wang YL, Cline GW, et al. Leptin Mediates a Glucose-Fatty Acid Cycle to Maintain Glucose Homeostasis in Starvation.[J]. Cell. 2018;172:234–248.e17.PubMedPubMedCentral
91.
Scarlett JM, Schwartz MW. Gut-brain mechanisms controlling glucose homeostasis.[J]. F1000 Prime Rep. 2015;7:12.
Metadata
Title
Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders
Authors
Yanduan Lin
Ziwei Zhang
Siyu Wang
Jinyan Cai
Jiao Guo
Publication date
01-12-2020
Publisher
Springer US
Keyword
Glucocorticoid
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2020
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09586-1

Other articles of this Issue 4/2020

Reviews in Endocrine and Metabolic Disorders 4/2020 Go to the issue

ReviewPaper

Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis

ReviewPaper

Review of the veteran affairs diabetes trial: Lessons learned

ReviewPaper

Multidisciplinary management of acromegaly: A consensus

ReviewPaper

Ketotherapy as an epigenetic modifier in cancer

ReviewPaper

Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management

ReviewPaper

Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits